Innovative antibiotics and antimicrobial peptides may dispel the threat of antibiotic resistance, but a joint effort of governments with the pharmaceutical industry is required, according to one presenter at the virtual EuCornea congress.
“On average, $2.5 billion are spent developing a single antibiotic, and that is not profitable for big pharma who have to make money for themselves and for the shareholders. My take is that governments have to join with industries not only in combating antimicrobial resistance, but also in developing new antimicrobial agents,” Harminder Dua, MD,
Uncategorized